Analysts Set Vaxcyte, Inc. (NASDAQ:PCVX) Target Price at $78.50

Shares of Vaxcyte, Inc. (NASDAQ:PCVX) have received an average recommendation of “Buy” from the five brokerages that are currently covering the stock, Marketbeat.com reports. Five analysts have rated the stock with a buy rating. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $78.50.

A number of analysts have commented on PCVX shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a research report on Friday, January 12th. Bank of America raised their price objective on Vaxcyte from $67.00 to $80.00 and gave the stock a “buy” rating in a research report on Tuesday, January 2nd. Mizuho started coverage on Vaxcyte in a research report on Thursday, December 7th. They issued a “buy” rating and a $69.00 price objective for the company. Finally, Needham & Company LLC raised their price objective on Vaxcyte from $73.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, February 28th.

Vaxcyte Trading Down 0.3 %

NASDAQ:PCVX opened at $68.31 on Friday. The business’s fifty day moving average price is $71.37 and its 200 day moving average price is $59.77. Vaxcyte has a 1-year low of $34.11 and a 1-year high of $82.04. The firm has a market capitalization of $7.41 billion, a price-to-earnings ratio of -16.54 and a beta of 0.91.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Tuesday, February 27th. The company reported ($1.82) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.93). During the same quarter in the previous year, the company posted ($0.73) earnings per share. Equities analysts forecast that Vaxcyte will post -4.18 earnings per share for the current year.

Insider Transactions at Vaxcyte

In other news, CFO Andrew Guggenhime sold 8,000 shares of the stock in a transaction that occurred on Thursday, January 18th. The stock was sold at an average price of $60.73, for a total value of $485,840.00. Following the completion of the transaction, the chief financial officer now directly owns 79,474 shares of the company’s stock, valued at approximately $4,826,456.02. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, CFO Andrew Guggenhime sold 8,000 shares of the stock in a transaction that occurred on Thursday, January 18th. The stock was sold at an average price of $60.73, for a total value of $485,840.00. Following the completion of the transaction, the chief financial officer now directly owns 79,474 shares of the company’s stock, valued at approximately $4,826,456.02. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Mikhail Eydelman sold 1,667 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $63.93, for a total value of $106,571.31. Following the sale, the senior vice president now directly owns 20,710 shares of the company’s stock, valued at $1,323,990.30. The disclosure for this sale can be found here. In the last ninety days, insiders sold 129,860 shares of company stock valued at $8,720,633. Corporate insiders own 3.60% of the company’s stock.

Institutional Investors Weigh In On Vaxcyte

Hedge funds and other institutional investors have recently bought and sold shares of the business. Parallel Advisors LLC increased its holdings in Vaxcyte by 155.3% during the 4th quarter. Parallel Advisors LLC now owns 411 shares of the company’s stock valued at $26,000 after purchasing an additional 250 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in shares of Vaxcyte in the 1st quarter valued at $30,000. KBC Group NV acquired a new stake in shares of Vaxcyte in the 4th quarter valued at $97,000. Bridgefront Capital LLC acquired a new stake in shares of Vaxcyte in the 4th quarter valued at $202,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Vaxcyte in the 4th quarter valued at $208,000. 96.78% of the stock is owned by institutional investors and hedge funds.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.